Background {#Sec1}
==========

Non-specific interstitial pneumonia (NSIP) is a type of interstitial idiopathic interstitial pneumonia (IIP) mainly affecting female non-smokers aged 40--60 years. Although more rigorous studies are needed, the prevalence of idiopathic NSIP (iNSIP) is estimated to be between 1 and 9 in 100,000 \[[@CR1], [@CR2]\]. NSIP can present as idiopathic or is associated with secondary conditions, such as connective tissue disease (CTD), human immunodeficiency virus infection, IgG4-related disease, bone marrow transplant, or toxin/drug-related conditions \[[@CR2]--[@CR4]\]. In addition, NSIP with connective tissue disease has recently been re-classified as interstitial pneumonia with autoimmune disease \[[@CR5]\].

Although the natural course of iNSIP is not yet known, previous studies showed that the prognosis of NSIP is favorable when compared with idiopathic pulmonary fibrosis (IPF) \[[@CR6]--[@CR8]\]. Corticosteroid and immunosuppressive agents (including azathioprine, cyclophosphamide, cyclosporine, and mycophenolate mofetil) are widely used and thought to be beneficial for patients with NSIP \[[@CR3], [@CR9], [@CR10]\]. However, changes to pulmonary function are not fully understood in both untreated and treated NSIP patients, especially in patients with low severity NSIP. Additionally, previous studies have addressed the risk factors and medical conditions associated with mortality rate, relapse, and progression of the disease, but the degree of response and factors affecting treatment have not been well studied \[[@CR10], [@CR11]\].

The Korean Interstitial Lung Disease (ILD) Research Group performed a nationwide survey to investigate the characteristics of patients with ILD, including iNSIP. In the present multicenter, nationwide study, we aimed to investigate the effect of treatment and the factors affecting the treatment outcome in patients with surgically proven-iNSIP.

Methods {#Sec2}
=======

Study population {#Sec3}
----------------

Figure [1](#Fig1){ref-type="fig"} shows the patient-flow chart. In total, 2186 idiopathic interstitial pneumonias (IIP) patients were registered by the Korean ILD Research Group, which includes pulmonologists from 54 University hospitals across the country with more than 500 beds starting 2006, from January 1, 2003, to December 31, 2007. Patients with a history of using medication that could provoke ILD (e.g., amiodarone or cytotoxic agent), and had a collagen-vascular disease were excluded from the study. In addition, patients with granulomatous diffuse parenchymal lung disease (e.g., sarcoidosis) or a rare form of ILD (e.g., lymphangioleiomyomatosis or pulmonary Langerhans cell histocytosis) were initially excluded from the study. NSIP was diagnosed based on the American Thoracic Society/European Respiratory Society (ATS/ERS) 2002 guidelines via a multidisciplinary approach by a pulmonologist, a chest specific radiologist, and pathologists \[[@CR12]\]. Patients diagnosed with IIP other than NSIP, including acute interstitial pneumonia, cryptogenic organizing pneumonia, desquamative interstitial pneumonia, lymphocytic interstitial pneumonia, nonspecific interstitial pneumonia, and respiratory bronchiolitis-associated interstitial lung disease, were excluded. Patients diagnosed clinically without a surgical lung biopsy were excluded. Additionally, patients for whom definitive diagnoses could not be made at each hospital, were reviewed by the Scientific Committee of the Korean Academy of Tuberculosis and Respiratory Diseases. Among the 261 patients with NSIP, those who developed a new CTD (*n* = 9) were excluded. Patients with hypersensitivity pneumonitis (HP), as indicated by the patient's history, clinical symptoms, and serologic test results, were also excluded from the study. Finally, 252 patients with iNSIP were analyzed in this study; 157 patients were followed-up within 1 year, and 95 patients were followed-up after \>1 year. Clinical (age, gender, smoking status, smoking amount, respiratory symptom, comorbidity, and outcome), physiological (pulmonary function test \[PFT\]), and laboratory (arterial blood gas analysis, C-reactive protein, anti-nuclear antibody \[ANA\], and rheumatoid factor) findings were retrospectively investigated. All patients' data were recorded in a web-based registry ([www.ild.or.kr](http://www.ild.or.kr)).Fig. 1Flow chart of the study population. Initially, 2186 patients with interstitial lung disease (ILD) were enrolled by the Korean study group between January 1, 2003, and December 31, 2007. A total of 261 surgically diagnosed patients with non-specific interstitial pneumonia (NSIP) were analyzed in this study; 1925 patients with a different diagnosis other than NSIP were excluded from this study. One hundred and fifty seven patients were followed-up within 1 year, and 95 patients were followed-up after \>1 year. Of these 95 patients, nine were in the conservative care group, and 86 in the treatment group. The treatment group was defined as those prescribed corticosteroid and/or immunosuppressant therapy, and conservative care group was defined as those who were only prescribed medication for symptom control. IPF: idiopathic pulmonary fibrosis, COP: cryptogenic organizing pneumonia, AIP: acute interstitial pneumonia, DIP: desquamative interstitial pneumonia, RB-ILD: respiratory bronchiolitis-associated interstitial lung disease, LIP: lymphocytic interstitial pneumonia

The 95 patients who were followed-up after \>1 year were divided into two groups: a no treatment group (*n* = 9) and a treatment group (*n* = 86). Patients who were prescribed corticosteroid or immunosuppressive agents were defined as "treatment group". The mean duration of treatment was 11.8 ± 8.3 months. The no treatment group patients were either only prescribed medication for symptom control or no medication at all.

To determine the effect of the treatment, the treatment group was further divided into two sub-groups. The response group was defined as patients with a change of ≥10% between the initial predicted forced vital capacity (FVC) (%) and the 1-year follow-up predicted FVC (%). The non-response group was defined as patients with a change of \<10% between the initial predicted FVC (%) and the 1-year follow-up predicted FVC (%).

Statistical analysis {#Sec4}
--------------------

Continuous variables were expressed as the mean ± standard deviation (SD) or median with interquartile range and compared by Student's t-test or a Mann Whitney U-test according to the distribution of patients. Categorical variables were presented as frequency (n) and percentage (%), and were analyzed by Fisher's exact test or Pearson's chi-square test. A Wilcoxon signed rank test or Paired t-test were conducted to compare the effect of treatment (initial PFT results vs 1-year follow-up results). A repeated measures ANOVA was conducted to compare the change in lung function between the response group and non-response group at 1 year. A logistic regression model was used to investigate the factors affecting the treatment outcome. An adjusted *p* value \<0.05 was considered to indicate significance. SPSS™ Version 22.0 (SPSS, Chicago, Illinois, USA), was used for all statistics analysis.

Results {#Sec5}
=======

Among 252 patients with iNSIP, 95 patients who were followed-up for over 1 year were analyzed to evaluate treatment response in this study. Table [1](#Tab1){ref-type="table"} shows the characteristics of the patients with iNSIP. The mean age was 57.1 ± 10.7 years, and females (65.1%) were predominant. The mean follow-up duration was 21.6 ± 16.6 months among all patients, and 32.1 ± 13.9 months in patients followed-up after \>1 year. Overall lung function was slightly decreased compared to normal; FVC (%) was 71.8 ± 18.4, forced expiratory volume (FEV~1~) (%) was 79.8 ± 20.9, and diffusing capacity of the lung for carbon monoxide (DL~CO~) (%) was 64.9 ± 21.3. Most of the patients were not smokers. Dyspnea (77.8%) and cough (72.6%) were the most common respiratory symptoms.Table 1Characteristics of the study populationTotal patients (*n* = 261)Patients followed up more than 1 year (*n* = 95)Age (year)57.1 ± 10.756.2 ± 10.3F: M170 (65.1): 91 (34.9)64 (67.4): 31 (32.6)^\*^Follow-up duration (month)21.6 ± 16.632.1 ± 13.9Pulmonary function test FVC (%)71.8 ± 18.472.5 ± 19.3 FEV~1~ (%)79.8 ± 20.981.1 ± 21.2 DLco (%)64.9 ± 21.364.7 ± 22.5^\*^Resting PaO~2~ mm Hg81.6 ± 17.386.7 ± 14.8Smoking status Never smoker169/241 (70.1)68/92 (73.9) Ex-smoker38/241 (15.8)16/92 (17.4) current smoker34/241 (14.1)8/92 (8.7)^\*^Smoking amount (Pys)29.3 ± 16.829.0 ± 15.2Initial symptom Dyspnea of exertion179/230 (77.8)64/80 (80.0) Cough159/219 (72.6)55/81 (67.9) Sputum69/186 (37.1)28/71 (39.4)^\*^Duration of symptom (month)6.2 ± 10.27.1 ± 12.0^\*^CRP (mg/dL)2.52 ± 6.211.56 ± 3.68ANA (positive)58/185 (31.4)18/59 (30.5)RF (positive)28/173 (16.2)11/59 (18.6)Outcome Alive157/261 (60.2)73/95 (76.8) Death26/261 (10.0)3/95 (3.2) Follow-up loss78/261 (29.9)19/95 (20.0)Note: Values in parentheses are percentages*F:M* female:male, *FVC*, forced vital capacity, *% pred* percentage of the predicted value, *FEV* ~*1*~ forced expiratory volume, *DL* ~*CO*~ diffusing capacity of the lung for carbon monoxide, *PaO* ~*2*~ arterial oxygen tension, *CRP* C-reactive protein, *ANA* antinuclear antibody, *RF* rheumatoid factor^**\***^Follow-up duration, smoking amount, duration of symptoms, and CRP showed a non-normal distribution in all patients^**\***^Resting PaO~2~ mm Hg, duration of symptom, and CRP showed a non-normal distribution in patients followed up for more than 1 year

Clinical, physiologic, and laboratory data for the no treatment group and treatment group are shown in Table [2](#Tab2){ref-type="table"}. More than 95% of patients were treated with steroid (Additional file [1](#MOESM1){ref-type="media"}: Table S1). In the treatment group, the median age was lower than that in the treatment group, although the difference was not significant (*p* = 0.061). Gender, follow-up duration, PFT results, smoking, initial respiratory symptoms, laboratory results, and comorbidities did not differ significantly between the groups (Table [2](#Tab2){ref-type="table"} and Additional file [1](#MOESM1){ref-type="media"}: Table S2). The change in lung function between the initial visit and the 1-year follow-up was investigated (Additional file [1](#MOESM1){ref-type="media"}: Table S3). In the no treatment group, although the FVC (%), FEV~1~ (%), and DL~CO~ (%) were increased 1 year after diagnosis, compared to the initial assessment, these changes in PFT were not significant (*p* = 0.276, *p* = 0.400, and *p* = 0.489, respectively). However, in the treatment group, these values were all significantly improved after 1 year (*p* \< 0.001, all).Table 2Characteristics according to treatment in patients followed-up for more than one yearNo treatment group (n = 9)Treatment group (n = 86)*P*-valueAge (year)63.0 (57.5, 66.0)55.0 (48.0, 64.3)0.061F: M5 (55.6): 4 (44.4)59 (68.6): 27 (31.4)0.467Follow-up duration (month)23.0 (20.5, 43.0)30.5 (20.8, 42.0)0.412Pulmonary function test FVC (%)83.0 (63.5, 91.0)69.5 (58.0, 87.0)0.291 FEV~1~ (%)100.0 (75.0, 104.5)80.0 (64.0, 95.0)0.111 DLco (%)70.5 (61.3, 79.3)48.0 (61.0, 80.0)0.165^\*^Resting PaO~2~ mm Hg85.0 (76.3, 91.0)89.0 (77.5, 98.0)0.442Smoking status0.302 Never smoker6/9 (66.7)62/83 (74.7) Ex-smoker1/9 (11.1)15/83 (18.1) current smoker2/9 (22.2)6/83 (7.2)Smoking amount (Pys)30.0 (15.0, −)30.0 (17.5, 44.0)0.539Initial symptom Dyspnea of exertion6/9 (66.7)58/71 (81.7)0.373 Cough6/9 (66.7)49/72 (68.1)1.000 Sputum4/6 (66.7)24/65 (36.9)0.204  ^\*^Duration of symptom (month)36.0 (3.5, 55.5)3.0 (1.0, 6.0)0.127^\*^CRP (mg/dL)0.48 (0.31, 1.87)0.45 (0.18, 1.31)0.407ANA (positive)3/6 (50.0)15/53 (28.3)0.357RF (positive)1/4 (25.0)10/55 (18.2)0.572Outcome0.303 Alive7/9 (77.8)66/86 (76.7) Death1/9 (11.1)2/86 (2.3) Follow-up loss1/9 (11.1)18/86 (20.9)Note: Values in parentheses are percentages*F:M* female:male, *FVC* forced vital capacity, *% pred* percentage of the predicted value, *FEV* ~*1*~ forced expiratory volume, *DL* ~*CO*~ diffusing capacity of the lung for carbon monoxide, *PaO* ~*2*~ arterial oxygen tension, *CRP* C-reactive protein, *ANA* antinuclear antibody, *RF* rheumatoid factorNote: data are expressed as the median with interquartile range or number with proportion (%)^**\***^CRP showed non-normal distribution in the no treatment group^**\***^Resting PaO~2~ mm Hg, duration of symptoms, and CRP showed a non-normal distribution in the treatment group

Table [3](#Tab3){ref-type="table"} also shows the difference in lung function between the initial PFT and 1-year follow-up PFT per the sero-positivity of ANA. The ANA results were available in 59 patients (62.1%). Forty-one patients (69.5%) with an initial negative ANA showed a significant improvement in lung function after 1 year; FVC (%) increased by 11.1%, FEV~1~ (%) by 11.3%, and DL~CO~ (%) by 12.1% (*p* = 0.008, *p* = 0.005, and p \< 0.001, respectively). However, sero-positive patients did not show a significant improvement in lung function after 1-year.Table 3Comparison between initial and 1-year follow-up lung function according to antinuclear antibody (ANA) positivityANA negative (*n* = 41)ANA positive (*n* = 18)InitialFollow-upp-valueInitialFollow-up*p*-valueFVC (%)72.1 ± 20.683.2 ± 15.50.00868.6 ± 19.576.4 ± 18.10.102FEV~1~ (%)80.1 ± 23.791.4 ± 19.70.00575.4 ± 19.083.7 ± 19.10.091DLco (%)68.7 ± 24.980.8 ± 26.0\<0.00162.9 ± 21.164.9 ± 23.40.568*FVC* forced vital capacity, *% pred* percentage of the predicted value, *FEV* ~*1*~ forced expiratory volume, *DL* ~*CO*~ diffusing capacity of the lung for carbon monoxide, *ANA* antinuclear antibody

We compared the baseline characteristics between the response group and non-response groups (Table [4](#Tab4){ref-type="table"}). Age and composition proportion of gender were similar between the groups (*p* = 0.895 and *p* = 0.705). In the response group, the follow-up duration was significantly longer than in the non-response group (*p* = 0.006), but the duration of respiratory symptoms was shorter (3.4 ± 4.4 months vs 7.1 ± 9.3 months, respectively; *p* = 0.038). With regard to pulmonary function, initial FVC (%), FEV~1~ (%), and DL~CO~ (%) were significant higher in the non-response group than in the response group (*p* \< 0.001, *p* \< 0.001, and *p* = 0.008, respectively). Current smokers were only found in the non-response group (*p* = 0.022). There were no significant differences in the initial respiratory symptoms, laboratory results, and comorbidities between the two groups (Table [4](#Tab4){ref-type="table"} and Additional file [1](#MOESM1){ref-type="media"}: Table S2). However, the proportion of ANA sero-positivity was higher in the non-response group than in the response group (*p* = 0.013). Furthermore, in the non-response group, two patients (4.5%) died during the follow-up period. Figure [2](#Fig2){ref-type="fig"} shows the change in pulmonary lung function over time (initial, 6 month, and 12 month) between the two groups. The FVC improved by 24.6%, and DL~CO~ improved by 20.2% after 1 year in the response group. However, in the non-response group, lung function after 1 year did not differ greatly from baseline. Therefore, there were significant differences in FVC and DL~CO~ between the two groups over time (*p* \< 0.001, and *p* = 0.002).Table 4Comparison of clinical characteristics between the response group and non-response groupResponse\
group (*n* = 42)Non-response\
group (*n* = 44)*p*-value^\*^Age (year)55.5 ± 11.355.8 ± 9.70.895F: M28 (66.7): 14 (33.3)31 (70.5): 13 (29.5)0.705Follow-up duration (month)36.6 ± 14.128.6 ± 12.20.006Pulmonary function test FVC (%)63.6 ± 17.679.9 ± 18.4\<0.001 FEV~1~ (%)71.7 ± 20.888.6 ± 19.9\<0.001 DLco (%)56.9 ± 19.070.5 ± 25.00.008Resting PaO~2~ mm Hg81.4 ± 17.092.5 ± 11.00.004Smoking status0.022 Never smoker30/40 (75.0)32/43 (74.4) Ex-smoker10/40 (25.0)5/43 (11.6) current smoker.6/43 (14.0)Smoking amount (Pys)26.5 ± 17.232.4 ± 15.10.415Initial symptom Dyspnea of exertion28/35 (80.0)30/36 (83.3)0.717 Cough26/36 (72.2)23/36 (63.9)0.448 Sputum13/33 (39.4)11/32 (34.4)0.675  ^\*^Duration of Symptom (month)3.4 ± 4.47.1 ± 9.30.038^\*^CRP (mg/dL)1.97 ± 5.011.19 ± 2.190.416ANA (positive)3/25 (12.0)12/28 (42.9)0.013RF (positive)2/25 (8.0)8/30 (26.7)0.092Outcome0.105 Alive30/42 (71.4)36/44 (81.8) Death.2/44 (4.5) Follow-up loss12/42 (28.6)6/44 (13.6)Note: Values in parentheses are percentages*F:M* female:male, *FVC* forced vital capacity, *% pred* percentage of the predicted value, *FEV* ~*1*~ forced expiratory volume, *DL* ~*CO*~ diffusing capacity of the lung for carbon monoxide, *PaO* ~*2*~ arterial oxygen tension, *CRP* C-reactive protein, *ANA* antinuclear antibody, *RF* rheumatoid factor^**\***^Duration of symptoms, and CRP showed a non-normal distribution in the response group^**\***^Age, duration of symptoms, and CRP showed a non-normal distribution in the non-response group Fig. 2Changes in lung function over time between the response group and non-response group. **a** Change in functional vital capacity (FVC) (%) over time between the two groups (*p* \< 0.001, Mean ± standard error (SE), **b** Change in the diffusing capacity of the lung for carbon monoxide (DL~CO~) (%) over time between the two groups (*p* = 0.002, Mean ± SE)

Multivariate analysis with logistic regression was conducted to investigate the risk factors for the non-response group (Table [5](#Tab5){ref-type="table"}). Age, gender, duration of respiratory symptoms, FVC (%), DL~CO~ (%), and arterial oxygen tension (PaO~2~) were examined. Although ANA showed a significant difference between the response group and non-response group, only 15 patients showed positivity (Table [4](#Tab4){ref-type="table"}). Thus, ANA was excluded from the multivariate analysis. The duration of symptoms at diagnosis was significantly associated with the response to treatment (hazard ratio (HR), 1.385; 95% CI, 1.058--1.813; *p* = 0.018). In addition, to identify the factors related to treatment failure, we defined patients with at least a 5% reduction in lung function reduction as "treatment failure" and performed logistic analysis. Thus, we found that age was significantly related to treatment failure. Older patients showed a tendency to experience treatment failure (Additional file [1](#MOESM1){ref-type="media"}: Table S4).Table 5Analysis of risk factors that affect treatment response by logistic regressionVariablesOdds ratio95% CI*p*-valueAge1.0260.913 to 1.1520.665Gender (M/F)0.5540.103 to 2.9970.493Duration of symptoms at diagnosis (Month)1.3851.058 to 1.8130.018FVC (% pred) at diagnosis1.0520.979 to 1.1310.170DL~CO~ (% pred) at diagnosis0.9950.951 to 1.0420.838PaO~2~ at diagnosis1.0140.954 to 1.0790.645*M/F* male/female, *FVC* forced vital capacity, *% pred* percentage of the predicted value, *DL* ~*CO*~ diffusing capacity of the lung for carbon monoxide, *PaO* ~*2*~ arterial oxygen tension, *CI* confidence interval

Discussion {#Sec6}
==========

Although the prognosis of iNSIP is better than that of IPF, the 5-year mortality rate is estimated to be 17.7% \[[@CR2]\]. To this date, there is no generally accepted guideline for the treatment of iNSIP; however, a previous study showed that corticosteroid and/or immunosuppressant therapy helped in maintaining or improving lung function in 81% patients with iNSIP \[[@CR9]\]. Our study showed that the serologic negativity of ANA was related with an improvement in pulmonary function, and patients who had a relatively shorter duration of initial respiratory symptoms responded to corticosteroids better than iNSIP patients with a longer duration of initial respiratory symptoms.

Since Bjoraker et al. \[[@CR13]\] reported the importance of the differentiation of NSIP from IPF, there has been much progression in the diagnosis of NSIP as a formally approved disease entity, but there are still no clear guidelines for diagnosis and treatment \[[@CR2], [@CR5], [@CR12], [@CR14]\]. Furthermore, some medical conditions (CTD-related ILD, hypersensitivity pneumonitis, cryptogenic organizing pneumonia, infection, or drug-induced lung disease) are related with NSIP, and therefore, the histologic characteristics of NSIP can be found in these diseases \[[@CR15]--[@CR18]\]. Due to the complexity of the diagnosis and low prevalence of NSIP, the factors predicting the response to treatment or the therapeutic effect are not well known \[[@CR1], [@CR6]\].

In the treatment group, lung function significantly improved after 1 year compared to the initial assessment; FVC (%) increased by 10.0%, FEV~1~ by 9.8%, and DL~CO~ by 8.4%. Park et al. \[[@CR9]\] showed that the change in FVC (%) occurred according to histopathological type and the survival outcome; treatment response was better in cellular-type, and there was a 25% increase in FVC (%) in the cellular-type/survivor group after 1 year. However, there was no improvement in FVC (%) in the fibrotic-type/non-survivor group. Additionally, in their study, the initial mean FVC (%) was 63.6 ± 14.6, which was lower than what we observed. Xu et al. \[[@CR8]\] also investigated the change in PFT results, but there was no significant improvement between the initial and follow-up lung function, possibly due to the non-fixed follow-up duration in their study. From our results, in the early stages of iNSIP, a clinician could anticipate that treatment would result in a 10% improvement in FVC (%) after 1 year. This information could help physicians predict the clinical course of patients with iNSIP, and plan adequate treatment modality.

Lee et al. \[[@CR10]\] reported similar results to our study, showing that the presence of ANA was significantly related with disease progression and a poor response to corticosteroids. They suggested that sero-positivity of ANA could be an early manifestation of systemic diseases associated with a poor outcome of NSIP. Xu et al. \[[@CR19]\] also showed that systemic autoimmune disease was significantly associated with increased mortality in NSIP patients (*p* = 0.023). Felicio et al. \[[@CR20]\] reported a higher production of collagen and elastic fibers in NSIP with collagen vascular disease than in iNSIP; in a cohort of 41 NSIP patients, an increase in elastic fibers \>1.5% was a significant risk factor for poor outcome (*p* = 0.01). In this study, the response group showed a lower proportion of ANA positivity than the non-response group (*p* = 0.013). Furthermore, negative ANA was associated with a significant improvement in lung function after 1 year.

Sawata et al. \[[@CR21]\] studied the influence of smoking in 31 NSIP patients over 2 years. They showed that the smoking group had a significantly worse outcome than the non-smoking group; smoking was significantly related with a lower %DL~CO~/alveolar ventilation (DL~CO~/VA) in both iNSIP (*p* = 0.009) and CTD-NSIP (*p* = 0.044), and progression free survival was worse in the smoker group (*p* = 0.0489). Furthermore, they showed that exacerbation was common in a heavy smoker. Similarly, in our study, the non-response group had a relatively higher total smoking patient number than the response group, and current smokers were only observed in the non-response group (Table [4](#Tab4){ref-type="table"}, *p* = 0.022). Marten et al. \[[@CR22]\] suggested that emphysema is higher in smokers with NSIP; therefore, cigarette smoking could be a pathogenic factor in a subset of NSIP patients. Thus, we presumed that smoking is related with NSIP pathogenesis, and could provoke a poor response to corticosteroids, causing a worse outcome.

To assess the severity in the study population, we calculated the ILD-GAP score, which is a clinical prognosis prediction model using age, gender, and two lung function parameters (FVC (%), DL~CO~ (%)) \[[@CR23], [@CR24]\]. Although the initial PFT results were lower in the response group, the majority of patients in this study had ILD-GAP stage I (96.6%, data not shown). Moreover, a relatively longer duration of respiratory symptoms was a risk factor for poor response to corticosteroids (Table [5](#Tab5){ref-type="table"}). This could mean that early treatment with corticosteroids and/or immunosuppressants might be more beneficial in the early stage of iNSIP, especially in ILD-GAP stage I patients. The physician should consider treatment of idiopathic NSIP in patients with respiratory symptoms, even if the severity of iNSIP is low.

There are some limitations to this study. First, it had a patient selection bias. This study was performed retrospectively and patients with ILD were enrolled in each hospital without a specific visit protocol. Therefore, 1-year follow-up PFT results exist in only 95 patients. Additionally, there have been major advances in the conceptualization of NSIP in recent years. In particular, it is currently speculated that iNSIP could be a type of autoimmune disease that is limited to the lungs or the respiratory manifestation of undifferentiated CTD \[[@CR5], [@CR18], [@CR25]\]. Initially, we only enrolled patients without autoimmune disease and nine patients who developed CTD were excluded from this study. Nevertheless, there could be differences between this study population's patients and currently diagnosed NSIP patients. Second, the NSIP subtype (cellular type, fibrotic type, or mixed) was not examined in this study. Previous studies showed that fibrotic NSIP was related with a poor prognosis and more frequent hospitalization \[[@CR9], [@CR11], [@CR26]\]. If the subtype was investigated, it would be more informative. Third, the initial dose of corticosteroids or immunosuppressive agents was not examined. Lee et al. \[[@CR10]\] reported that a low corticosteroid dose was significantly related with relapse, which could mean that the dose of corticosteroids administered could affect the response to treatment.

Conclusion {#Sec7}
==========

Our study showed that corticosteroid and/or immunosuppressant therapy was effective in iNSIP, resulting in an improvement in lung function after 1 year. Corticosteroid-based treatment was especially effective in iNSIP patients who showed sero-negativity for ANA and those who had a shorter duration of respiratory symptoms. These findings suggest that early treatment with corticosteroids and/or immunosuppressants could be therapeutically beneficial in iNSIP patients, even if the disease is at an early stage. Further prospective, large, and well-designed studies are needed to confirm the factors affecting treatment effect.

Additional file. {#Sec8}
================

Additional file 1: Table S1.Treatment modality in treatment group (*n* = 86). **Table S2.** Comorbidities of study population. **Table S3.** Comparison between initial and 1-year follow-up lung function according to treatment. **Table S4.** Analysis of risk factors that associated with treatment failure (by logistic regression). (DOCX 26 kb)
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